Tumor Cell State Linked to Low Angiogenesis Identified in Lung Adenocarcinoma
A SCGB3A2-high tumor cell state in lung adenocarcinoma shows low angiogenesis and is associated with extracellular PGK2 and angiostatin signals.
A SCGB3A2-high tumor cell state in lung adenocarcinoma shows low angiogenesis and is associated with extracellular PGK2 and angiostatin signals.
A case report describes an 80-year-old woman with metastatic urachal adenocarcinoma whose colorectal cancer-based therapy, including third-line trifluridine/tipiracil plus bevacizumab, ...
A meta-analysis of six randomized trials found that adding PD-1/PD-L1 inhibitors to chemotherapy was associated with longer progression-free and overall ...
A 10-eye retrospective series associated subretinal tenecteplase-assisted vitrectomy with rapid displacement of fovea-involving hemorrhage and improved vision at 12 months, ...
New cost-of-illness analyses reveal that age-related macular degeneration and diabetic macular edema cost Bulgaria €545.7 million between 2017 and 2023 ...
A five-year Chinese case report documents two retinal arterial macroaneurysms in one eye following starkly divergent courses, with one lesion ...
A network meta-analysis of eight randomized trials finds that immune checkpoint inhibitors combined with anti-VEGF therapy outperform other immunotherapy combinations ...
NYU Langone ophthalmology researchers presented trial evidence that a ROCK inhibitor eyedrop can spare corneal transplants, staged therapies for corneal ...
In a groundbreaking advancement in pediatric ophthalmology, researchers have unveiled a novel therapeutic strategy that significantly mitigates retinal vasculopathy associated ...
In the quest for understanding and treating neovascular age-related macular degeneration (nAMD), a significant breakthrough has been unveiled in the ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.